Neos Therapeutics Receives U.S. FDA Approval of Adzenys ER™ (amphetamine) Extended-Release Oral Suspension for the Treatment of ADHD in Patients 6 Years and Older
September 15, 2017 16:39 ET
|
Neos Therapeutics, Inc
DALLAS and FORT WORTH, Texas, Sept. 15, 2017 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq:NEOS), a pharmaceutical company focused on developing, manufacturing and commercializing innovative...
Neos Therapeutics Announces Launch of Cotempla XR-ODT™ (methylphenidate) Extended-Release Orally Disintegrating Tablets for the Treatment of ADHD in Patients 6 to 17 Years Old
September 05, 2017 08:00 ET
|
Neos Therapeutics, Inc
DALLAS and FORT WORTH, Texas, Sept. 05, 2017 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq:NEOS), a pharmaceutical company focused on developing, manufacturing and commercializing innovative...
Neos Therapeutics to Participate in Three September Conferences
August 30, 2017 07:30 ET
|
Neos Therapeutics, Inc
DALLAS and FORT WORTH, Texas, Aug. 30, 2017 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (NASDAQ:NEOS), a pharmaceutical company focused on developing, manufacturing and commercializing innovative...
Neos Therapeutics Reports Second Quarter 2017 Financial Results
August 08, 2017 07:00 ET
|
Neos Therapeutics, Inc
DALLAS and FORT WORTH, Texas, Aug. 08, 2017 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq:NEOS), a pharmaceutical company focused on developing, manufacturing and commercializing innovative...
Neos Therapeutics to Host Second Quarter 2017 Financial Results Conference Call on August 8, 2017
August 02, 2017 07:30 ET
|
Neos Therapeutics, Inc
DALLAS and FORT WORTH, Texas, Aug. 02, 2017 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (NASDAQ:NEOS), a pharmaceutical company focused on developing, manufacturing and commercializing innovative...
Neos Therapeutics Announces Proposed Offering of Common Stock
June 26, 2017 16:01 ET
|
Neos Therapeutics, Inc
DALLAS and FORT WORTH, Texas, June 26, 2017 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq:NEOS), a pharmaceutical company focused on developing, manufacturing and commercializing innovative...
Neos Therapeutics Announces FDA Approval of Cotempla XR-ODT™ (methylphenidate) Extended-Release Orally Disintegrating Tablets for the Treatment of ADHD in Patients 6 to 17 Years Old
June 19, 2017 21:46 ET
|
Neos Therapeutics, Inc
DALLAS and FORT WORTH, Texas, June 19, 2017 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq:NEOS), a pharmaceutical company focused on developing, manufacturing and commercializing innovative...
Neos Therapeutics to Present at the JMP Securities 2017 Life Sciences Conference
June 14, 2017 07:30 ET
|
Neos Therapeutics, Inc
DALLAS/FORT WORTH, Texas, June 14, 2017 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (NASDAQ:NEOS), a pharmaceutical company focused on developing, manufacturing and commercializing innovative...
Neos Therapeutics to Present at Jefferies 2017 Global Healthcare Conference
May 30, 2017 07:30 ET
|
Neos Therapeutics, Inc
DALLAS and FORT WORTH, Texas, May 30, 2017 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (NASDAQ:NEOS), a pharmaceutical company focused on developing, manufacturing and commercializing innovative...
Neos Therapeutics to Present at 2017 UBS Global Healthcare Conference
May 16, 2017 07:30 ET
|
Neos Therapeutics, Inc
DALLAS and FORT WORTH, Texas, May 16, 2017 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (NASDAQ:NEOS), a pharmaceutical company focused on developing, manufacturing and commercializing innovative...